Gain Therapeutics (GANX) Other Non-Current Assets (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Other Non-Current Assets of $36085.0 for Q1 2026, up 10.89% year-over-year from $32542.0 in Q1 2025, and down 0.58% quarter-over-quarter from $36296.0 in Q4 2025.
Gain Therapeutics (GANX) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Gain Therapeutics' Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $36085.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 10.89% year-over-year to $36085.0; the TTM figure through Mar 2026 stood at $36085.0 (up 10.89% YoY), while the FY2025 annual figure was $36296.0, up 13.04% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $36085.0, down from $36296.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $36296.0 in Q4 2025, with the low at $16534.0 in Q2 2022.
- The 5-year median for Other Non-Current Assets is $31145.0 (2023), against an average of $29236.9.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets sank 79.31% in 2022, then soared 92.35% in 2025.
- Gain Therapeutics' Other Non-Current Assets stood at $30818.0 in 2022, then grew by 10.39% to $34021.0 in 2023, then declined by 5.62% to $32109.0 in 2024, then rose by 13.04% to $36296.0 in 2025, then fell by 0.58% to $36085.0 in 2026.
- Business Quant data shows GANX's Other Non-Current Assets at $36085.0 in Q1 2026, $36296.0 in Q4 2025, and $36117.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | 35,589.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35,589.00 |
| Mar 31, 2026 | 36,085.00 |
| Dec 31, 2025 | 36,296.00 |
| Sep 30, 2025 | 36,117.00 |
| Jun 30, 2025 | 33,752.00 |
| Mar 31, 2025 | 32,542.00 |
| Dec 31, 2024 | 32,109.00 |
| Sep 30, 2024 | 33,873.00 |
| Jun 30, 2024 | 17,547.00 |
| Mar 31, 2024 | 17,613.00 |
| Dec 31, 2023 | 34,021.00 |
| Sep 30, 2023 | 31,145.00 |
| Jun 30, 2023 | 17,734.00 |
| Mar 31, 2023 | 31,122.00 |
| Dec 31, 2022 | 30,818.00 |
| Sep 30, 2022 | 28,859.00 |
| Jun 30, 2022 | 16,534.00 |
| Mar 31, 2022 | 30,860.00 |
| Dec 31, 2021 | 31,279.00 |
| Sep 30, 2021 | 30,868.00 |